Skip to main content
Clinical Trials/NCT03601091
NCT03601091UnknownNot Applicable

RANDOMİZED,DOUBLE-BLİND TRİAL OF EFFECT OF DEXMEDETOMİDİNE AND MİDAZOLAM SEDATİON ON HEART RATE VARİABİLİTY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY

Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital1 site in 1 country80 target enrollmentStarted: March 22, 2018Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
80
Locations
1
Primary Endpoint
Heart rate variability

Study Overview

Brief Summary

The parasympathetic tone reduction and sympathetic tone enhancement, which are components of the autonomic nervous system (ANS) activity, increase the likelihood of malignant arrhythmias leading to ventricular fibrillation. Malignant arrhythmias are associated with high mortality and morbidity after coronary artery bypass graft (CABG) surgeries. Heart rate variability (HRV) is a physiological indicator of the effects of ANS activity on heart rate and is associated with a prognostic value for cardiac mortality. Dexmedetomidine has been shown to improve myocardial perfusion, reduce arrhythmia incidence, reduce inflammatory response, and reduce mortality in patients with coronary artery disease. The aim of this study investigate the effects of dexmedetomidine electrophysiologically on cardiac autonomic system by using HRV analysis for the purpose of sedation in patients who were followed up in the intensive care unit after coronary artery bypass graft surgery

Detailed Description

Malignant arrhythmias are associated with high mortality and morbidity after coronary artery bypass graft (CABG) operations. Heart rate variability (HRV) is a physiological indicator of the effects of activity on heart ANS rate and has prognostic value for cardiac mortality. Spectral analysis of HRV can provide an assessment of adrenergic and cholinergic system activities during anesthesia. With the "power spectral" analysis of HRV, important clinical information can be obtained about the effects of anesthesia on the autonomic nervous system and the central nervous system. Decrease in HRV has a prognostic value for cardiac-induced mortality. The disease, which is transferred to intensive care unit (ICU) after CABG, is sedated with different medicines until the time of extubation. One commonly used sedative drug is deksmedetomidine, an α2 receptor agonist. Alpha 2 (α2) receptor agonist drugs reduce myocardial oxygen consumption and heart rate with sympatholytic properties. Therefore, deksmedetomidine can be safely and effectively used in patients undergoing cardiac surgery without pro-tachyarrhythmic and / or negative inotropic effects.In this study, it was aimed to investigate electrophysiologic effects of cardiac autonomic system by using HRV analysis in dexmedetomine and midazolam patients who underwent elective CABG and were used for sedation in the postoperative period.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Masking Description

DOUBLE BLINDED

Eligibility Criteria

Ages
25 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients with pre-operative normal sinus rhythm
  • Ejection fraction (EF)> 45% on echocardiography (echocardiography) examination
  • 25 and 65 years of age will be included.

Exclusion Criteria

  • Atrial fibrillation , atrial flutter, supraventricular tachycardia , AV block, ventricular extrasystole
  • Cardiopulmonary bypass have been reported in patients with diabetes mellitus (DM),
  • Chronic obstructive pulmonary disease (COPD),
  • Previous cerebrovascular event will be excluded from the study.
  • Patients receiving high-dose inotropic drug support after surgery (inotropic score of> 10 in the first 24 hours) and
  • Patients re-operated for bleeding revision will be removed from the study.

Arms & Interventions

PR

Active Comparator

PRECEDEX 200 mcg 2 ml,0,3 mcg/kg/h, intravenous continue infusion, 4 hours.

Intervention: Precedex 200 MCG in 2 ML Injection (Drug)

DO

Active Comparator

DORMICUM 5MG/5 ML, 0,1 mg/kh/h, intravenous continue infusion for 4 hours

Intervention: DORMICUM 5MG/5 ML (Drug)

Outcomes

Primary Outcomes

Heart rate variability

Time Frame: 24 hours

Low and high frequency of heart rate regarding with aritmia incidence

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Sponsor Class
Other Gov
Responsible Party
Principal Investigator
Principal Investigator

mustafa emre gürcü

Medical Doctor

Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

Study Sites (1)

Loading locations...

Similar Trials